title: Aripiprazole and Impulse-Control Disorders: A Recent FDA Warning and a Case Report.
authors.affiliation: Cramond Clinic, Department of Psychiatry, The Queen Elizabeth Hospital, Adelaide, Australia.
authors.forename: Rohan
authors.initials: R
authors.lastname: Dhillon
authors.affiliation: Department of Psychiatry, Flinders University, Adelaide, Australia.|South Australian Health and Medical Research Institute, Adelaide, Australia.
authors.forename: Tarun
authors.initials: T
authors.lastname: Bastiampillai
authors.affiliation: claudia.cao@sa.gov.au.|Cramond Clinic, Department of Psychiatry, The Queen Elizabeth Hospital, Adelaide, Australia.
authors.forename: Claudia Z
authors.initials: CZ
authors.lastname: Cao
authors.affiliation: Medical School, University of Adelaide, Adelaide, Australia.
authors.forename: Thomas G
authors.initials: TG
authors.lastname: Eckert
authors.affiliation: Cramond Clinic, Department of Psychiatry, The Queen Elizabeth Hospital, Adelaide, Australia.
authors.forename: Prashant
authors.initials: P
authors.lastname: Tibrewal
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000068180:Aripiprazole / Q000009:adverse effects* / Q000627:therapeutic use; D007174:Disruptive, Impulse Control, and Conduct Disorders / Q000139:chemically induced*; D006801:Humans; D008297:Male; D012559:Schizophrenia / Q000188:drug therapy; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D014150:Antipsychotic Agents; D000068180:Aripiprazole